Dedicated to Werner Duechting for his inspiring work on tumor modeling and his inspiration inducing character on the occasion of his 75 th birthday
INTRODUCTION
The majority of cancer modeling techniques developed up to now adopt the straightforward bottom-up approach focusing on the better understanding and quantification of rather microscopic tumor dynamics mechanisms and the investigation of crucial biological entity interdependences including i.a. tumor response to treatment in the generic investigational context. To this end several combinations of mathematical concepts, entities and techniques have been developed and/or recruited and appropriately adapted. They include i.a. population dynamics models (Guiot et al 2006) , cellular automata and hybrid techniques (Duechting and Vogelsaenger 1981; Duechting et al 1992; Ginsberg et al 1993; Kansal et al 2000; Stamatakos et al 2001a Stamatakos et al , 2001b Zacharaki et al 2004) , agent based techniques (Deisboeck et al 2001) , diffusion related continuous and finite mathematics treatments (Murray 2003 Oncology Group (ISOG) ( In Silico Oncology Group , Stamatakos et al 2001c Stamatakos et al , 2002 Stamatakos et al , 2006b Stamatakos et al , 2006c Stamatakos et al , 2006d Stamatakos et al , 2006e, 2007a Stamatakos et al , 2007b Stamatakos et al , 2009a Dionysiou et al 2004 Dionysiou et al , 2006a Dionysiou et al , 2006b Dionysiou et al , 2006c 2008; Antipas et al 2004 Antipas et al , 2007 Stamatakos and Uzunoglu 2006b; Stamatakos and Dionysiou 2009 ) . Macroscopic data, including i.a. anatomic and metabolic tomographic images of the tumor, provide the framework for the integration of available and clinically trusted biological information pertaining to lower and lower biocomplexity levels such as clinically approved histological and molecular markers. However, the method does also provide a powerful framework for the investigation of multiscale tumor biology in the generic investigational context.
From the mathematical point of view the top-down simulation method presented is primarily a discrete mathematics method, although continuous mathematics (continuous functions, differerential equations) are used in order to tackle specific aspects of the models such as pharmacokinetics and cell survival probabilities based on pharmacodynamical and radiobiological models. Adoption of the discrete approach as the core mathematical strategy of the method has been dictated by the obvious fact that from the cancer treatment perspective it is the discrete i.e. the integer number of the usually few biological cells surviving treatment and their discrete mitotic potential categorization (stem cells, progenitor cells of various mitotic potential levels and differentiated cells) that really matter. These discrete entities and quantities in conjunction with their complex interdependences may give rise to tumor relapse or to ensure tumor control over a given time interval following completion of the treatment course. Cell cycle phases have a clearly discrete character too. Moreover, the properties of the different cell phases may vary immensely from the clinical significance perspective. A classical example is the lack of effect of cell cycle specific drugs on living tumor cells residing in the resting G0 phase.
It is noted that complex interdependencies of microscopic factors in the surroundings of the cells such as oxygenation, nutrient supply and molecular signals emitted by other cells play a critical role in the mitotic fate of tumor cells. Their effect is taken into account in the method through the local mean values of the corresponding model parameters. To this end imaging, histological and molecular data is exploited as will be described further down.
Due to the numerical character of the method a careful and realistically thorough numerical analysis concerning consistency, convergence and sensitivity/stability issues is absolutely necessary before any application is envisaged. A discussion of this critical issue is included in Section 5.
Tumor neovascularisation is taken into account in an indirect yet pragmatic way by exploiting grey level and/or color information contained within slices of tomographic imaging modalities sensitive to blood perfusion and/or the metabolic status of the tumor. (Stamatakos et al 2001a (Stamatakos et al ,2002 Dionysiou et al 2004 Dionysiou et al , 2007 Marias et al 2007) . The reason for adopting the above mentioned strategy rather than developing or integrating detailed tumor angiogenesis models is that no microscopic information regarding the exact mesh of the neovascularization capillaries throughout the tumor can be currently extracted from clinically utilized imaging modalities. Nevertheless, the microscopic functional capillary density distribution over the tumor can be grossly estimated based on various imaging modalities such as T1 gadolinium enhanced MRI in the case of glioblastoma multiforme (GBM) and arterial spin labelling (ASL) MRI.
Precursors of the method can be traced in the well established and clinically applicable disciplines of pharmacology and radiobiology. Integration of molecular biology in the top-down method may be viewed as the introduction of a perturbator or adaptor of the cellular and higher biocomplexity level parameters. In such a way in vivo measurable clinical manifestation of tumor dynamics is placed the foreground. This is one of the reasons why the method is gaining wider and wider acceptance within the clinical and the industrial environment including the emergent domain of in silico oncology (Stamatakos et al 2002 (Stamatakos et al , 2007b (Stamatakos et al , 2009a Graf and Hoppe 2006; Graf et al 2007 Graf et al , 2009 ). Both the large scale European Commission (EC) and Japan funded ACGT research and development (R&D) project (ACGT) and the EC funded ContraCancrum R&D project (ContraCancrum) have adopted the top-down method as their core cancer simulation method. It is worth noting that in both projects the role of clinicians is prominent. A biomedical engineering concept and construct tightly associated with the method, the Oncosimulator, which is currently under clinical adaptation, optimization and validation is also sketched.
In order to convey the core philosophy of the method to the reader in a concise way a symbolic mathematical formulation of the top-down method in terms of a hypermatrix and discrete operators is introduced. Two specific models of tumor response to chemotherapeutic and radiotherapeutic schemes/schedules are briefly outlined so as to exemplify the method's application potential. The chapter concludes with a discussion of several critical aspects including numerical analysis, massive parallel code execution, associated technologies, extensions and validation within the framework of clinico-genomic trials and future challenges and perspectives.
A rather encouraging fact as far as industrial and eventually clinical translation of the method is concerned is that both the top-down method outlined and the Oncosimulator have been selected and endorsed by a worldwide leading medical technology company and now constitute modules of their research and development line (ContraCancrum). One of the envisaged final products of this endeavor is a radiotherapy treatment planning system based on both physical and multiscale biological optimization of the spatiotemporal dose administration scheme. A clinical trial based validation process for the system is currently at the final stage of its detailed formulation.
THE ONCOSIMULATOR
The Oncosimulator can be defined as a concept of multilevel integrative cancer biology, a complex algorithmic construct, a biomedical engineering system and (eventually in the future) a clinical tool which primarily aims at supporting the clinician in the process of optimizing cancer treatment in the patient individualized context through conducting experiments in silico i.e. on the computer. Oncosimulator. The expectedly optimal therapeutic scheme or schedule is administered to the patient.
Subsequently, the predictions regarding the finally adopted and applied scheme or schedule are compared with the actual tumor course and a negative feedback signal is generated and used in order to optimize the Oncosimulator.
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A BRIEF OUTLINE OF THE BASICS OF THE ISOG TOP-DOWN METHOD
The Multilevel Matrix of the Anatomical Region of Interest
The anatomical region of interest, primarily including the tumor and possibly adjacent normal tissues and edema, in conjunction with its biological, physical and chemical dynamics is represented by a multilevel matrix i.e. a
Matrix of (Matrices of (Matrices…of (Scalars or Vectors or Matrices )…)).
The multilevel matrix is created by a cubic discretization mesh which is virtually superimposed upon Discrete time is used. An important discretization aspect of the method is the mean time spent in the phase of an equivalence class by the biological cells belonging to the equivalence class (Stamatakos et al 2001c (Stamatakos et al , 2002 Dionysiou et al 2004 Dionysiou et al , 2006 Stamatakos and Dionysiou 2009b) . In order to allow for spatiotemporal perturbations of critical parameter values throughout the tumor and also avoid artificial cell synchronizations due to quantization, use of pseudo-random numbers is extensively made (Monte Carlo technique).
Practical Considerations Regarding the Construction of the Discretization Mesh
Collection of the appropriate mono-modality or far better multi-modality tomographic data of the patient such as slices of T1 weighted contrast enhanced MRI, T2 weighted MRI, CT, PET or other modalities, image segmentation, slice interpolation, three dimensional reconstruction of the anatomical entities of interest centered at the tumor, and eventually fusion of more than one modality images constitute the initial steps for the creation of the discretization mesh covering and discretizing the anatomical region of interest. Processed microscopic data (histological, molecular) are then utilized in order to enhance the patient individualization of the hypermatrix.
The basics of the top-down method
The multilevel matrix corresponding to the anatomical region of interest describes explicitly or implicitly the biological, physical and chemical dynamics of the region. The following parameters are used in order to identify a cluster of biological cells belonging to a given equivalence class within a geometrical cell of the mesh at a given time point:
I. the spatial coordinates of the discrete points of the discretization mesh with spatial indices i, j, k respectively. Each discrete spatial point lies at the center of a geometrical cell of the discretization mesh.
II. the temporal coordinate of the discrete time point with temporal index l and "oxygen and nutrient provision level insufficient for tumor cell proliferation". Obviously the binary character of the oxygen and nutrient provision level is to be considered only a first simplifying approximation. More elaborate descriptions have been proposed and applied (Stamatakos et al 2002 (Stamatakos et al , 2006d Dionysiou et al 2004 Dionysiou et al , 2006a Antipas et al 2004) .
ii. number of biological cells E. Differential expansion or shrinkage or more generally geometry and mechanics handling.
F.
Updating the local oxygen and nutrient provision level following application of the rest of algorithm sets at each time step
It is noted that the outcome of appropriate processing of the molecular and/or histopathological data via e.g. molecular networks and signaling pathways is used as a perturbator of the cell survival probabilities included in algorithm set "C" so as to considerably enhance patient individualization of the simulation.
A realistic estimate of the extent of such perturbations for a given tumor type subclass in the framework of a clinico-genomic trial is achieved in a stepwise way. Initial rough modifications of the cell survival probabilities based on the baseline-pretreatment data, pertinent literature information and logic are subsequently corrected through utilization of the corresponding post treatment data via a process of parameter fitting.
Obviously the above mentioned concepts and briefly outlined steps cannot convey all the details needed for the simulation to run. Their role is rather to identify and decompose the major conceptual mathematical and computational steps than to list all modeling details. The interested reader is referred to the website of the In Silico Oncology Group where they may find lists of pertinent publications providing detailed descriptions of several top-down multilevel cancer models including i.a.
assumptions, mathematical treatment, numerical aspects such as convergence and quantization error minimization, sensitivity analysis, validation, applications and suggested extensions.
It is worth noting that discrete simulation under certain constraints can efficiently replace analytical solutions to a wide range of mathematical problems which, although being formulated in terms of 
EXAMPLES OF APPLICATIONS OF THE ISOG TOP-DOWN METHOD -RESULTS
In this section two indicative models denoted by Model A and Model B are briefly outlined so as to exemplify the application potential of the method in the clinical context.
Model A: Tumor Response to Chemotherapeutic Schedules
Model A is a four dimensional, patient specific top-down simulation model of solid tumor response to chemotherapy treatment response models. Figure 2 depicts the simplified cytokinetic model of a tumor cell that has been proposed and adopted in Model A. The cytotoxicity produced by TMZ is primarily modeled by a delay in the S phase compartment (TDS) which is denoted by "Delay due to the effect of chemotherapy" in the diagram of Both irradiation schedules start on the first day of the first week of treatment. HF-64.8 is completed on day 37 after initiation of treatment whereas AHF-48 is completed on day 19. According to the graphs, before completion of the AHF course cell kill due to AHF irradiation is more pronounced than cell kill induced by the HF scheme. This can be explained by the fact that a higher total dose has been administered to the tumor by the AHF scheme whereas for the period under consideration both schemes are characterized by the same time intervals between consecutive sessions. In case that not all living 
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DISCUSSION
Since the top-down multilevel method presented is a numerical method, a thorough convergence and sensitivity/stability analysis that includes the study of multiple parameter interdependences is necessary before any application is envisaged. Numerical analysis should satisfactorily cover at least those regions of the abstract parameter space that correspond to the envisaged applications. It is noted that of particular importance is the creation of the baseline tumor constitution by exploiting the relevant multilevel data available. Convergence of the tumor initialization has to be ensured. All of the above Critical constraints imposed by toxicological limits of the treatment affected normal tissues should also be taken into account in order to judge whether or not a candidate scheme could be toxicologically acceptable. This issue may be addressed by exploiting the outcome of eventually relevant clinical trials and in particular of their phase I results. Ideally, direct multiscale spatiotemporal simulation of the effects of a given candidate scheme on specific normal tissues would provide quantitatively refined predictions. Nevertheless, due to the extremely high complexity of the homeostatic mechanisms governing normal tissue dynamics, the large number of normal tissue functional aspects and the potential induction of serious late effects by treatment such as radiotherapy, clinical translation of the second scenario seems to be a long term enterprise (Antipas et al 2007) .
Since many solid tumors are microscopically inhomogeneous in space, the applications presented so far essentially make use of the mean values of certain biological parameters over each imaging based segmented sub-region of the tumor ( Stamatakos et al 2002 , 2006d , 2006e, 2007b , 2006a 2008; Antipas et al 2004 Antipas et al , 2007 . and tumor cell -local environment interactions in the microscopic setting can in principle be studied. In order to implement the above scenarios, the density of the discretization mesh should considerably increase, deeper level partitioning into more equivalence (sub-)classes has to be introduced into the multilevel matrix of the anatomical region of interest and the algorithm sets should be extended accordingly. However, such an approach dictates a sharp increase in computing memory and time demands and therefore tumor size must be kept small if restrictions in these resources apply, as is usually the case.
Following appropriate adaptation of specific modeling modules or equivalently algorithm sets such as the "C" set referring to cell killing etc. the top-down method outlined is in principle able to simulate tumors of any shape, size, geometry, macroscopic distribution of the metabolic or neovascularisation Referring to the molecular level from the generic investigational standpoint, a large number of mechanisms, such as pathways leading to apoptosis or survival, that can be informed by available molecular data can be readily integrated into top-down models by applying the summarize and jump strategy of bio-data and bio-knowledge integration across bio-complexity scales (Stamatakos et al 2009a) . This is in fact one of the actions currently taking place within the framework of the ContraCancrum project (ContraCancrum). However, if the same biocomplexity level is viewed from the clinical perspective, care has to be taken so that only those characteristics and /or mechanisms whose predictive potential has been proved and established in the clinical setting -normally through clinical trials -may be incorporated into the models.
Regarding the envisaged clinical translation of top-down based models and systems, including the Oncosimulator, a sine qua non prerequisite is a systematic, formal and strict clinical validation.
Designing the models so as to mimick actual clinical or far better clinico-genomic trials seems to be the optimal way to achieve this goal (Stamatakos et al. , 2007a Graf and Hoppe 2006; Graf 2007 Graf , 2009 . Therefore, involvement of clinicians in the model and system design and validation process should start at the very beginning of the endeavor (Graf 2007 (Graf , 2009 . Real clinicogenomic trials can provide invaluable multiscale data (imaging, histological, molecular, clinical, treatment) before, during and after a treatment course so as to best adapt and optimize the models and subsequently validate them. This is one of the core tasks of both the ACGT (ACGT) and the ContraCancrum R&D (ContraCancrum) projects. Nephroblastoma and breast cancer are the tumor types addressed by ACGT whereas gliomas and lung cancer are the ones addressed by ContraCancrum.
A further important challenge is to develop reliable, efficient, highly versatile and user friendly technological platforms which, following clinical adaptation, optimization and validation of the models would facilitate translation of oncosimulators into the clinical practice so as to efficiently support, enhance and accelerate patient individualized treatment optimization. Advanced image processing, visualization and parallel code execution modules are but a few of the components necessary to achieve this goal. Both the ACGT and ContraCancrum R&D projects constitute exemplary initiatives towards this direction.
In summary both the top-down multilevel cancer simulation method briefly outlined above and the
Oncosimulator have been designed so as to be readily optimizable, extensible and adaptable to changing clinical, biological, and research envirionments. Thus both entities, being primarily multiscale physics and biomedical engineering geared, have a pragmatic and evolutionary character. 
